Supplementary Figure 1A from Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints

PDF file - 78K</p

Supplementary Figure 1B from Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints

PDF file - 109K</p

CCR Translation for This Article from Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints

CCR Translation for This Article from Resampling Phase III Data to Assess Phase II Trial Designs and Endpoint

Supplementary Figure Legend 1 from Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints

PDF file - 59K</p

Maximum acute toxicity.

<p>Maximum acute toxicity.</p

Patient and tumor characteristics.

<p>Patient and tumor characteristics.</p

Supplemental Table from Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Supplementary Table 1. Toxicities during the first cycle of FOLFIRI plus bevacizumab. Number of patients (%) is indicated. Toxicities were included if they occurred in at least 10% of patients or if they were grade 3 or greater, and if they were at least possibly related to treatment.</p

supplemental figure from Genotype-Guided Dosing Study of FOLFIRI plus Bevacizumab in Patients with Metastatic Colorectal Cancer

Supplementary Figure 1. Progression-free survival (PFS) overall (A), by UGT1A1 genotype (B), and by irinotecan dose (C).</p

Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy - Fig 2

<p>Freedom from locoregional failure (A), freedom from distant metastasis (B), freedom from colostomy (C), and overall survival (D) for patients with HPV+ disease.</p

Treatment outcomes and HPV characteristics for an institutional cohort of patients with anal cancer receiving concurrent chemotherapy and intensity-modulated radiation therapy - Fig 1

<p>Freedom from locoregional failure (A), freedom from distant metastasis (B), freedom from colostomy (C), and overall survival (D) for all patients receiving IMRT with concurrent chemotherapy.</p